Evidence map›Paper›PMID 42891231›Full record

ArticleFrontiers in oncology2026

Madona Gjona, Seval Turna, Cömert Şen, Ahmet Özkan, Kağan Avcı, Murat Ulusan, Gülsüm Ak, Vakur Olgaç, Semra Demokan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Madona GjonaInstitute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Türkiye.
Seval TurnaInstitute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Türkiye.
Cömert ŞenDepartment of Otorhinolaryngology-Head and Neck Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Ahmet ÖzkanDepartment of Otorhinolaryngology-Head and Neck Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Kağan AvcıDepartment of Otorhinolaryngology-Head and Neck Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Murat UlusanDepartment of Otorhinolaryngology-Head and Neck Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Gülsüm AkDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry, Istanbul University, Istanbul, Türkiye.
Vakur OlgaçDepartment of Oral Pathology, Faculty of Dentistry, Istanbul University, Istanbul, Türkiye.
Semra DemokanDepartment of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Aberrant promoter DNA methylation represents an early molecular alteration in oral carcinogenesis and has emerged as a potential source of molecular biomarkers for oral cancer. Although Experimental design: Results: Conclusions: This study provides the first comprehensive evaluation of

Indexed as

DNA methylationepigenetic biomarkersgene expressionliquid biopsyoral premalignant lesionsoral squamous cell carcinomaRNF152

Identifiers

PMID42891231
PMCPMC13674023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.